Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

British Journal of Clinical Pharmacology
Juha GrönlundKari Laine

Abstract

Oxycodone is an opioid analgesic that is metabolized mainly in the liver by cytochrome P450 (CYP) 2D6 and 3A4 enzymes. So far, the effects of CYP2D6 or CYP3A4 inhibitors on the pharmacokinetics of oxycodone in humans have not been systematically studied. Drug interactions arising from CYP2D6 inhibition most likely have minor clinical importance for oral oxycodone. When both of CYP2D6 and CYP3A4 pathways are inhibited, the exposure to oral oxycodone is increased substantially. The aim of this study was to find out whether the inhibition of cytochrome P450 2D6 (CYP2D6) with paroxetine or concomitant inhibition of CYP2D6 and CYP3A4 with paroxetine and itraconazole, altered the pharmacokinetics and pharmacological response of orally administered oxycodone. A randomized placebo-controlled cross-over study design with three phases was used. Eleven healthy subjects ingested 10 mg of oral immediate release oxycodone on the fourth day of pre-treatment with either placebo, paroxetine (20 mg once daily) or paroxetine (20 mg once daily) and itraconazole (200 mg once daily) for 5 days. The plasma concentrations of oxycodone and its oxidative metabolites were measured for 48 h, and pharmacological (analgesic and behavioural) effects were eva...Continue Reading

References

Jul 18, 1970·British Medical Journal·J G Hannington-Kiff
Jan 1, 1984·British Journal of Clinical Pharmacology·B M Stone
Jan 1, 1993·European Journal of Clinical Pharmacology·K BrøsenL F Gram
Jan 1, 1996·Clinical Pharmacology and Therapeutics·R F KaikoP D Goldenheim
Feb 1, 1996·Journal of Clinical Anesthesia·M KirvelaK T Olkkola
Jan 1, 1996·European Journal of Clinical Pharmacology·U JeppesenK Brøsen
Apr 1, 1997·Clinical Pharmacology and Therapeutics·K M JalavaP J Neuvonen
Dec 9, 1997·Clinical Pharmacology and Therapeutics·K M KaukonenP J Neuvonen
Jan 1, 1999·Clinical Pharmacology and Therapeutics·T HeiskanenE Kalso
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Er-jia WangWilliam W Johnson
Mar 15, 2002·Drugs·Antona J WagstaffKaren L Goa
Feb 14, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kirk M BertelsenDavid J Greenblatt
Mar 25, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bojan LalovicDanny D Shen
Sep 1, 2004·Journal of Pain and Symptom Management·Edward MichnaRobert N Jamison
Sep 28, 2004·Basic & Clinical Pharmacology & Toxicology·Camilla Staahl, Asbjørn Mohr Drewes
Feb 8, 2005·The Journal of Allergy and Clinical Immunology·Thomas M File
Mar 31, 2005·Journal of Pharmaceutical Sciences·Emma BoströmMargareta Hammarlund-Udenaes
May 21, 2005·Clinical Chemistry·Johanna SistonenAntti Sajantila
May 24, 2005·Journal of Pain and Symptom Management·Eija Kalso
Dec 1, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Eric Prommer
Jan 30, 2007·Clinical Pharmacology and Therapeutics·S-M HuangL J Lesko
May 6, 2008·British Journal of Anaesthesia·K T S Pattinson
Oct 7, 2008·European Journal of Clinical Pharmacology·Nora M HagelbergKlaus T Olkkola
Dec 19, 2008·European Journal of Pain : EJP·Katri HamunenEija Kalso
Sep 17, 2009·Journal of Clinical Pharmacology·Juha GrönlundKari Laine

❮ Previous
Next ❯

Citations

Sep 22, 2010·European Journal of Clinical Pharmacology·Oliver KummerStephan Krähenbühl
Jan 12, 2011·European Journal of Clinical Pharmacology·Masaaki WatanabeYukinao Kohda
Jul 8, 2011·European Journal of Clinical Pharmacology·Trine Naalsund AndreassenOla Dale
Mar 1, 2012·European Journal of Clinical Pharmacology·Kristin MoksnesOla Dale
Apr 15, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Janet HardyBruce Charles
Dec 28, 2011·British Journal of Anaesthesia·T I SaariH Schwilden
Dec 22, 2010·Antimicrobial Agents and Chemotherapy·Juha GrönlundKari Laine
Jan 7, 2014·Drug Metabolism and Pharmacokinetics·Tomoko OtaKenji Kinoshita
Dec 12, 2012·Pharmacogenomics and Personalized Medicine·Pascal H VuilleumierRuth Landau
Feb 14, 2014·Journal of Analytical Toxicology·Natalie M ElderJoseph D Ma
Mar 8, 2013·Trends in Pharmacological Sciences·Klaus T OlkkolaEija A Kalso
May 2, 2014·Journal of Pain and Symptom Management·Aleksandra Kotlinska-LemieszekPål Klepstad
Mar 16, 2013·Expert Opinion on Drug Metabolism & Toxicology·Romina KlimasGerd Mikus
Sep 4, 2015·Clinical Pharmacokinetics·Prajakta S BadriRajeev M Menon
Dec 19, 2012·Journal of Pain and Symptom Management·Jeffrey Gudin
Nov 26, 2010·Forensic Science International : Synergy·A SajantilaB Budowle
Nov 3, 2015·European Journal of Pharmacology·Sebastiano Mercadante
Jan 11, 2012·Pain Practice : the Official Journal of World Institute of Pain·Tuija H NieminenKlaus T Olkkola
Jan 19, 2012·Anaesthesia·R LandauJ C Kraft
Jul 12, 2012·Clinical Genetics·R BranfordJ R Ross
Apr 24, 2012·Expert Opinion on Pharmacotherapy·Hannu KokkiSari Sjövall
Jan 15, 2014·Neonatal Network : NN·Denise Maguire
Jun 24, 2017·Clinical Pharmacology and Therapeutics·Kristiina CajanusEija Kalso
Dec 22, 2017·Addiction Biology·Douglas M McMillanRachel F Tyndale
Sep 25, 2018·Journal of Clinical Pharmacology·Shinya Ito
Sep 18, 2018·Pharmacogenetics and Genomics·Rachel HuddartTeri E Klein
Mar 21, 2019·Journal of Hospice and Palliative Nursing : JHPN : the Official Journal of the Hospice and Palliative Nurses Association·Mary Jo Quinn
Jan 12, 2020·Biopharmaceutics & Drug Disposition·Jaana RytkönenAki T Heikkinen
Apr 1, 2012·Anesthesiology and Pain Medicine·Mohammad MoradiSaeid Safari
Jan 18, 2019·Clinical Pharmacokinetics·Mari KinnunenMerja Kokki
Nov 1, 2013·British Journal of Pain·Roman CreggHiroe Sato
Sep 7, 2018·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Anne Leuppi-TaegtmeyerStephan Krähenbühl
Jun 4, 2021·Clinical and Translational Science·Lin XuRodney Rouse
Sep 29, 2021·Molecular Neurobiology·Nicole ArguellesRachel F Tyndale

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.